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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERAbdominal Contributions in Heart Failure 485Frederik H. Verbrugge, Matthias Dupont, Paul Steels, Lars Grieten, Manu Malbrain,
W. H. Wilson Tang, Wilfried Mullens
Verbrugge and colleagues explore the crosstalk between the abdomen, the heart, and the
kidneys in congestive heart failure (CHF). The splanchnic vasculature holds approximately
25% of the blood volume during normal situations with a large capacitance volume that can
be affected by venous vasoconstriction. Alterations in hepatic function can contribute to renal
vasoconstriction. Finally, gut-derived hormones might inﬂuence sodium homeostasis, while
impaired intestinal barrier function secondary to congestion may allow entrance of bowel
toxins into the circulatory system. Understanding these interactions better might lead to new
diagnostic opportunities as well as treatment strategies to achieve decongestion.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYDES and BMS in STEMI 496
Tullio Palmerini, Giuseppe Biondi-Zoccai, Diego Della Riva, Andrea Mariani, Manel Sabaté,
Marco Valgimigli, Giacomo Frati, Elvin Kedhi, Pieter C. Smits, Christoph Kaiser, Philippe Genereux,
Soren Galatius, Ajay J. Kirtane, Gregg W. Stone
Palmerini and colleagues investigated the relative safety and efﬁcacy of different drug-eluting
stents (DES) and bare-metal stents (BMS) in patients with ST-segment elevation myocardial
infarction (STEMI) using a network meta-analysis. Twenty-two randomized control trials
comparing currently U.S.-approved DES or DES with BMS in patients with STEMI were
compiled. At 1-year follow-up, cobalt-chromium everolimus-eluting stents (CoCr-EES)
were associated with signiﬁcantly lower rates of cardiac death or myocardial infarction (MI)
compared to BMS. CoCr-EES, paclitaxel-eluting stents, and sirolimus-eluting stents, but
not zotarolimus-eluting stents, had signiﬁcantly lower rates of 1-year target vessel
revascularization than BMS. These results suggest steady improvements in STEMI PCI
outcomes with the evolution from BMS to ﬁrst-generation and now second-generation DES.(continued on page A-26)
AUGUST 6, 2013 (continued) A-26ANTIPLATELET THERAPYEffect of Smoking Status on Clopidogrel and Prasugrel Pharmacodynamics 505
Paul A. Gurbel, Kevin P. Bliden, Douglas K. Logan, Dean J. Kereiakes, Kenneth C. Lasseter,
Alex White, Dominick J. Angiolillo, Thomas D. Nolin, Jen-Fue Maa, William L. Bailey,
Joseph A. Jakubowski, Clement K. Ojeh, Young-Hoon Jeong, Udaya S. Tantry, Brian A. Baker
Gurbel and colleagues investigated the effects of smoking on the pharmacokinetics (PK)
and pharmacodynamics (PD) of clopidogrel and prasugrel therapy. Patients were randomized
to clopidogrel (75 mg daily) or prasugrel (10 mg daily) for 10 days and crossed over after a
14-day washout. During clopidogrel therapy, inhibition of platelet aggregation (IPA) was
lower and P2Y12 reaction units (PRU) and vasodilator-stimulated phosphoprotein
phosphorylation-platelet reactivity index were higher in nonsmokers than smokers. Greater
antiplatelet effects were seen with prasugrel treatment compared to clopidogrel irrespective of
smoking status. These results demonstrate lower clopidogrel active metabolite exposure and
PD effects of clopidogrel in nonsmokers relative to smokers.
Editorial Comment: Laurent Bonello, Corinne Frère, Franck Paganelli, Marc Laine, p. 513HEART FAILURETiming of Hemoconcentration in Acute Heart Failure 516
Jeffrey M. Testani, Meredith A. Brisco, Jennifer Chen, Brian D. McCauley, Chirag R. Parikh,
W. H. Wilson Tang
Hemoconcentration, deﬁned as increases in measured hemoglobin and hematocrit, during
the treatment of decompensated heart failure (HF) indicate a reduction in intravascular
volume. Testani and colleagues reviewed the outcomes of patients hospitalized with HF.
Hemoconcentration occurred in one-half of patients. Early hemoconcentration was deﬁned
as prior to the midway point of the hospitalization, regardless of its duration. Patients with
late hemoconcentration had higher average daily loop diuretic doses, greater weight loss, and
shorter length of stay compared to early hemoconcentration, and higher survival rates
compared to those with no hemoconcentration. These results suggest a beneﬁt to
progressively reducing plasma volume prior to discharge.(continued on page A-27)
AUGUST 6, 2013 (continued) A-27HEART RHYTHM DISORDERSSilent Atrial Fibrillation, Stroke, and Diabetes 525
Raffaele Marfella, Ferdinando Carlo Sasso, Mario Siniscalchi, Mario Cirillo, Pasquale Paolisso,
Celestino Sardu, Michelangela Barbieri, Maria Rosaria Rizzo, Ciro Mauro, Giuseppe Paolisso
Marfella and colleagues performed quarterly 48-h Holter monitors to determine if subclinical
episodes of atrial ﬁbrillation (AF) were associated with an increased risk of silent cerebral
infarct (SCI) and stroke in diabetic patients. The diabetic subjects were signiﬁcantly more
likely to have at least 1 subclinical episode of AF lasting at least 10 min than a control group
of nondiabetics (9.0% vs. 1.6%). Diabetic patients with silent episodes of AF had higher
baseline prevalence of SCI (61% vs. 29%) and higher stroke events (17.3% vs. 5.9%) during
the follow-up period. Subclinical episodes of AF occur frequently in type 2 diabetic patients
and signiﬁcantly increase the risk of neurologic events.HEART RHYTHM DISORDERSCognitive Dysfunction Post-Ablation for Atrial Fibrillation 531
Caroline Medi, Lisbeth Evered, Brendan Silbert, Andrew Teh, Karen Halloran, Joseph Morton,
Peter Kistler, Jonathan Kalman
Medi and colleagues performed a detailed battery of neurocognitive testing before and after
atrial ﬁbrillation (AF) ablation procedures and included a control group of AF patients that
did not undergo ablation and another control group of patients with supraventricular
tachycardia (SVT) that underwent ablation. Patients were administered 8 neuropsychological
tests at baseline and at 2 days and 3 months post-operatively. The incidence of post-operative
cognitive dysfunction (POCD) at day 2 post-procedure was 28% in patients with AF, 13% in
patients with SVT, and 0% in AF control patients. At day 90, the incidence of POCD in
patients who underwent AF ablation was 13% to 20%, while it was 3% in patients with SVT,
and 0% in AF control patients. Higher left atrial access time was associated with POCD on
univariate analysis.
Editorial Comment: Eric N. Prystowsky, Benzy J. Padanilam, p. 540(continued on page A-28)
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Michael Poon, Michael Cortegiano, Alexander J. Abramowicz, Margaret Hines, Adam J. Singer,
Mark C. Henry, Peter Viccellio, Jeffrey C. Hellinger, Summer Ferraro, Annie Poon, Gilbert L. Raff,
Szilard Voros, Michael E. Farkouh, Pamela Noack
Poon and colleagues conducted a retrospective multivariate analysis of emergency
department (ED) patients presenting with chest pain to assess the impact of coronary
computed tomographic angiography (CCTA) versus standard evaluation on admissions rate,
length of stay, major adverse cardiovascular event rates, recidivism rates, and downstream
resource utilization. The admission rate was lower for CCTA (14% vs. 40%). There were no
difference in the rates of deaths and acute myocardial infarction. Standard evaluation patients
were 7 times more likely to undergo invasive coronary angiography without revascularization
with similar rates of revascularization. Routine use of CCTA in the ED evaluation of chest
pain may safely reduce healthcare resource utilization.PERIPHERAL ARTERY DISEASEAlternative Ankle-Brachial Index and Mortality 553Kevin T. Nead, John P. Cooke, Jeffrey W. Olin, Nicholas J. Leeper
Traditionally, the ankle-brachial index (ABI) is calculated using the higher of the dorsalis
pedis (DP) and posterior tibial (PT) arteries divided by the higher brachial pressure. Nead
and colleagues studied an alternative ABI using the lower of the DP or PT blood pressures.
The ABI was calculated in a cohort of patients undergoing coronary angiography. Sixteen
percent had a traditionally calculated ABI of <0.90. A total of 22% of the remaining subjects
had an ABI of <0.90 using the alternative ABI method. Adjusted Cox regression models
showed that the alternative-PAD group had an increased risk for all-cause and cardiovascular
mortality compared to the patients with normal ABIs by both methodologies. These results
suggest that the alternative ABI identiﬁes patients at increased CV risk that are classiﬁed as
normal with the traditional ABI calculation.
Editorial Comment: William R. Hiatt, p. 560
